Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
Top Cited Papers
- 3 March 2005
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (9) , 895-904
- https://doi.org/10.1056/nejmsa042220
Abstract
Previous reviews of phase 1 oncology trials reported a rate of response to treatment of 4 to 6 percent and a toxicity-related death rate of 0.5 percent. These results may not reflect the rates in current phase 1 oncology trials.Keywords
This publication has 29 references indexed in Scilit:
- Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical TrialsJAMA, 2004
- The needs of science vs the needs of patients: ethical concerns in cancer clinical trials.Cleveland Clinic Journal of Medicine, 2003
- Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agentsBritish Journal of Cancer, 2003
- Ethics of Phase 1 Oncology StudiesJAMA, 2003
- Phase I Cancer Trials: A Crucible of Competing PrioritiesInternational Anesthesiology Clinics, 2001
- Phase I Cancer Trials: A Collusion of MisunderstandingHastings Center Report, 2000
- Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trialsAnnals of Oncology, 2000
- Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in JapanCancer Chemotherapy and Pharmacology, 1994
- Responses and toxic deaths in Phase I clinical trialsAnnals of Oncology, 1990
- On the nature and ethics of phase I clinical trials of cancer chemotherapiesPublished by American Medical Association (AMA) ,1982